Statistics from Altmetric.com
Although long-term suppression of experimental arthritis has been reported for liposomal glucocorticoids, direct effects on subsequent flare-up reactions have not been investigated. The glucocorticoid dexamethasone phosphate (DXM-P) was encapsulated in large, non-PEGylated liposomes (DPPC/DPPG/Chol, 50/10/40 mol%, size: 295 (SD 15) nm) and its therapeutic efficacy was compared with free (non-liposomal) drug in rat antigen-induced arthritis (AIA). The specific aim was to assess the therapeutic persistence of an initial acute phase treatment with liposomal DXM-P on the induction of a subsequent flare-up reaction.
Intravenous injection of liposomal DXM-P (1.25 mg/kg body weight) at 6, 24 and 48 h following arthritis induction completely suppressed joint swelling. The tight treatment schedule was chosen based on the rapid kinetics of arthritis development in this model (6 h: half-maximal swelling; 24–48 h peak arthritis). No rebound was seen until day …
Competing interests SP is founder and shareholder of Novosom AG.
UR and RWK contributed equally.
Provenance and Peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.